product name Lomeguatrib
Description: Lomeguatrib, also known as PaTrin-2, is a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase with IC50 of 5 nM. Lomeguatrib is also a nontoxic low-molecular weight pseudosubstrate that has the ability to inactivate MGMT. Lomeguatrib can be used with temozolomide (TMZ) for GBM treatment. Lomeguatrib sensitized MGMT-activity-bearing A375P cells to temozolomide (TMZ), but it failed to affect the effect of dacarbazine (DTIC).
References: J Med Chem. 1998;41(26):5265-71; Br J Cancer. 2005;93(10):1152-6; Int J Cancer. 2000;85(2):248-52.
326.17
Formula
C10H8BrN5OS
CAS No.
192441-08-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 65 mg/mL (199.3 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
PaTrin-2
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19410977
| In Vitro |
In vitro activity: Lomeguatrib inactivates O6-alkylguanine-DNA-alkyltransferase (ATase) with a IC50 10-fold lower than O6-Benzylguanine. Lomeguatrib inhibits the activity of ATase in Raji cells with IC50 of 10 nM. Lomeguatrib effectively inactivates MGMT in MCF-7 cells with IC50 of ~6nM ). Lomeguatrib (10 μM ) substantially increases the growth inhibitory effects of temozolomide in MCF-7 cells (D60= 10 μM with Lomeguatrib vs 400 μM without). Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Lomeguatrib (20 mg/kg/day for 5 days) combined with temozolomide (100 mg/kg/day for 5 days) produces a substantial tumour growth delay: median tumour quintupling time is increased by 22 days without any significant increase in toxicity, while neither of the two drugs administrated along show any antitumor activity. Lomeguatrib inactivates ATase and enhances the anti-tumour effect of temozolomide in A375M human melanoma xenografts model. Lomeguatrib, at a single dose of 20 mg/kg i.p., produces complete ATase depletion in tumor within 2 hr. Temozolomide (100 g/kg/day) significantly delays growth of the A375M tumour xenograft with an estimated delay in the time for tumour to quintuple in size of 9.6 days. Addition of Lomeguatrib to temozolomide significantly enhances the latter’s effect, delaying the quintupling time a further 8.7 days. Moreover, the Lomeguatrib combination results in considerably less toxicity (0/9 vs. 2/9 deaths; 6.84% weight loss vs. 9.48%). Lomeguatrib alone has no significant effect on tumour growth. |
| Animal model | |
| Formulation & Dosage | |
| References | J Med Chem. 1998 Dec 17;41(26):5265-71; Br J Cancer. 2005 Nov 14;93(10):1152-6; Int J Cancer. 2000 Jan 15;85(2):248-52. |
